Great news from/for Xeltis (located in hub Catalyst of Twice Eindhoven on the TU/e Campus)! It is one of seven European companies selected to become a member of the prestigious research network ArtMoMa. This network is funded by the European Commission's Horizon 2020 program.
Xeltis is one of seven European companies selected to join the prestigious research network ArtMoMa.
The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. Xeltis is one of the pioneers in this field. They are developing self-growing heart valves from the body's own tissue for children with congenital heart failure.
ArtMoMa is built on synergies and complementarity between leading scientists, including four Nobel laureates: Professors Jean-Marie Lehn - a member of Xeltis' Scientific Advisory Board and a pioneer in supramolecular chemistry, the science behind ETR and Xeltis' living implants - Ben Feringa, Jean-Pierre Sauvage and Fraser Stoddart. "The selection of Xeltis for ArtMoMa is a great opportunity to join forces with leading scientists and institutions to advance supramolecular chemistry research," explained Xeltis CTO and co-founder Martijn Cox, "and is a testament to the competitive contribution of our research team." ArtMoMa includes world-class institutions and companies - from start-ups to SMEs to global players from across Europe. It is an innovative research network funded for four years by the European Commission's H2020 program. Read more information about the program here: https://artmoma-h2020.eu/partners/
Sources: http://xeltis.com/xeltis-joins-prestigious-research-network-artmoma/
Also appeared in Eindhovens Dagblad 19-05-2020
